Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.

Cerebrospinal fluid B cells do not predict multiple sclerosis progression

10 Aug 2017

B cell subtypes in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients are not predictors of disease progression, expanded disability status scale (EDSS) progression or conversion to clinical definite MS (CDMS), a recent longitudinal prospective study has shown.

Over a median follow-up period of 7.9 years, CSF samples were extracted from 40 clinically isolated syndrome (CIS), 27 relapsing remitting MS (RRMS), two secondary progressive MS (SPMS) and nine primary progressive MS (PPMS) patients. A control group of 40 patients with other neurological diseases (OND) was included.

Older age at baseline (odds ratio [OR], 1.7; 95 percent CI, 1.0 to 3.0; p=0.041) was the only significant prognostic factor for MS progression after comparing the SPMS and PPMS with the CIS and RRMS patients.

There were no significant associations found for sex (OR, 0.3; 0.0 to 3.8; p=0.380), duration of disease (OR, 1.3; 0.9 to 1.9; p=0.097), CD19+CD138- cells (OR, 0.0; 0.0 to 7.8; p=0.166) or CD19+CD138+ cells (OR, 0.5; 0.0 to 26.3; p=0.736).

Similarly, age at baseline (OR, 1.1; 1.0 to 1.1; p=0.012) was the only significant prognostic factor for EDSS progression. CD19+CD138- (OR, 0.1; 0.0 to 1.2; p=0.077) and CD19+CD138+ (OR, 1.6; 0.4 to 6.7; p=0.531) cells were not significantly correlated.

On the other hand, flow cytometry analysis showed that the majority of B cells in the CSF of MS patients were either CD19+CD138- mature B cells or CD19+CD138+ plasmablasts. At follow-up, the CSF composition of CIS, RRMS and SPMS patients were significantly different from the OND controls (p<0.001). PPMS CSF composition did not significantly differ from OND CSF composition.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.